Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

Video

Related Videos
Somedeb Ball, MBBS
Lori A. Leslie, MD
Changchun Deng, MD, PhD
Rebecca Klisovic, MD
Guenther Koehne, MD, PhD
Sunil Iyer, MD
Ibrahim Aldoss, MD
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Sunil Iyer, MD
Related Content
OncLive On Air Podcast Recap

Revisit Every OncLive On Air Episode From April 2024

May 13th 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Anthony M. Hunter, MD

Novel Targets Beyond the JAK-STAT Pathway Aim to Push Myelofibrosis Treatment Forward

May 10th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023
Podcast
Harout Semerjian, CEO of GlycoMimetics

Uproleselan Plus Chemotherapy Misses OS End Point in R/R AML

May 6th 2024
Article
Leland Metheny, MD, Case Western Reserve University

AML, ALL, and Glioblastoma Multiforme Clinical Trials Seek to Push the Needle Forward

May 6th 2024
Article